Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Naomi Hunder(Fred Hutch Cancer Center), Cassian Yee(The University of Texas MD Anderson Cancer Center), Jianhong Cao(Fred Hutch Cancer Center), Rebecca M. Rodmyre(Fred Hutch Cancer Center), Herschel Wallen(Fred Hutch Cancer Center), Deborah W. Hendricks(Fred Hutch Cancer Center), Sacha Gnjatic(Tisch Hospital), Achim A. Jungbluth(Gynecologic Oncology Group), John A. Thompson(Fred Hutch Cancer Center), J. Zachary Reilly(Fred Hutch Cancer Center)
Cited by 903
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k